Evidence map›Paper›PMID 41471105›Full record

ArticlePharmaceutics2025

Compound KTI-2338 Inhibits ACVR1 Receptor Signaling in Fibrodysplasia Ossificans Progressiva.

Neeltje M Rosenberg, Lidiia Zhytnik, Lisanne E Wisse, Esmée Botman, Jennifer L Lachey, E Marelise W Eekhoff, Dimitra Micha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Neeltje M RosenbergDepartment of Internal Medicine, Section Endocrinology and Metabolism, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Lidiia ZhytnikRare Bone Disease Center Amsterdam, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0003-4682-0402
Lisanne E WisseRare Bone Disease Center Amsterdam, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0002-9367-5730
Esmée BotmanDepartment of Internal Medicine, Section Endocrinology and Metabolism, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Jennifer L LacheyKeros Therapeutics, Inc., 1050 Waltham Street, Lexington, MA 02421, USA.
E Marelise W EekhoffDepartment of Internal Medicine, Section Endocrinology and Metabolism, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0001-5399-676X
Dimitra MichaRare Bone Disease Center Amsterdam, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0001-7890-4411

Funding

Keros Therapeutics, Inc N.A.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

activin AACVR1ALK2 inhibitorBMPfibroblastsfibrodysplasia ossificans progressivaheterotopic ossification

Identifiers

PMID41471105
PMCPMC12736380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.